AU2004315197B2 - Identification of novel IgE epitopes - Google Patents
Identification of novel IgE epitopes Download PDFInfo
- Publication number
- AU2004315197B2 AU2004315197B2 AU2004315197A AU2004315197A AU2004315197B2 AU 2004315197 B2 AU2004315197 B2 AU 2004315197B2 AU 2004315197 A AU2004315197 A AU 2004315197A AU 2004315197 A AU2004315197 A AU 2004315197A AU 2004315197 B2 AU2004315197 B2 AU 2004315197B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- ige
- antibodies
- cells
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004315197A AU2004315197B2 (en) | 2004-02-02 | 2004-07-29 | Identification of novel IgE epitopes |
AU2009202408A AU2009202408A1 (en) | 2004-02-02 | 2009-06-16 | Identification of novel IgE epitopes |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/002892 WO2004070010A2 (en) | 2003-02-01 | 2004-02-02 | A method for generating high affinity antibodies |
AUPCT/US2004/002894 | 2004-02-02 | ||
PCT/US2004/002894 WO2004070011A2 (en) | 2003-02-01 | 2004-02-02 | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
AUPCT/US2004/002892 | 2004-02-02 | ||
PCT/US2004/024360 WO2005075504A1 (en) | 2004-02-02 | 2004-07-29 | IDENTIFICATION OF NOVEL IgE EPITOPES |
AU2004315197A AU2004315197B2 (en) | 2004-02-02 | 2004-07-29 | Identification of novel IgE epitopes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009202408A Division AU2009202408A1 (en) | 2004-02-02 | 2009-06-16 | Identification of novel IgE epitopes |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004315197A1 AU2004315197A1 (en) | 2005-08-18 |
AU2004315197B2 true AU2004315197B2 (en) | 2009-06-04 |
Family
ID=34841291
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004315197A Active AU2004315197B2 (en) | 2004-02-02 | 2004-07-29 | Identification of novel IgE epitopes |
AU2009202408A Abandoned AU2009202408A1 (en) | 2004-02-02 | 2009-06-16 | Identification of novel IgE epitopes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009202408A Abandoned AU2009202408A1 (en) | 2004-02-02 | 2009-06-16 | Identification of novel IgE epitopes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1718669A4 (zh) |
JP (1) | JP2008507474A (zh) |
KR (4) | KR101562114B1 (zh) |
CN (1) | CN102702359A (zh) |
AU (2) | AU2004315197B2 (zh) |
CA (1) | CA2552999A1 (zh) |
SG (2) | SG183683A1 (zh) |
WO (1) | WO2005075504A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008019131A2 (en) * | 2006-08-04 | 2008-02-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating ige-mediated diseases |
US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
EP2121762A1 (en) * | 2007-02-15 | 2009-11-25 | AstraZeneca AB | BINDING MEMBERS FOR IgE MOLECULES |
AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
BRPI0822098A2 (pt) * | 2007-12-21 | 2015-06-30 | Glaxosmithkline Biolog Sa | Componente para uma vacina contra malária, vacina para malária, processo para a preparação do componente, uso do componente, e, método de tratar um paciente suscetível às infecções por plasmodium |
KR101634058B1 (ko) | 2008-12-09 | 2016-06-27 | 화이자 백신스 엘엘씨 | IgE CH3 펩티드 백신 |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
JP7128191B2 (ja) * | 2017-01-06 | 2022-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療抗IgE抗体並びにその方法及び組成物 |
AU2019244666A1 (en) * | 2018-03-26 | 2020-10-08 | Novartis Ag | Methods of treating chronic spontaneous urticaria using ligelizumab |
JP2024521390A (ja) | 2021-06-14 | 2024-05-31 | ノバルティス アーゲー | 抗IgE抗体を含有する医薬製剤 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0263655A2 (en) * | 1986-10-03 | 1988-04-13 | Dainippon Pharmaceutical Co., Ltd. | Novel peptides having antiallergic activity |
EP0957111A2 (en) * | 1998-04-09 | 1999-11-17 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
WO2000023477A2 (en) * | 1998-10-20 | 2000-04-27 | University Of Sheffield | Immunoglobulin variants |
WO2000050461A1 (en) * | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
WO2000074716A2 (en) * | 1999-06-08 | 2000-12-14 | Smithkline Beecham Biologicals S.A. | Ige peptides for allergy immunotherapy |
WO2002016409A2 (en) * | 2000-08-22 | 2002-02-28 | Glaxosmithkline Biologicals S.A. | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
EP1195161A2 (en) * | 2000-08-30 | 2002-04-10 | Pfizer Products Inc. | Anti-IgE vaccines |
WO2002034288A2 (en) * | 2000-10-27 | 2002-05-02 | Smithkline Beecham Biologicals S.A. | Vaccine for treating allergy |
EP1262491A2 (en) * | 2001-05-22 | 2002-12-04 | Pfizer Products Inc. | Non-anaphylactogenic IgE vaccines |
WO2003092714A2 (en) * | 2002-04-30 | 2003-11-13 | Glaxosmithkline Biologicals S.A. | Peptide variants of ige constrained by beta-lactam bond |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69333484T2 (de) * | 1992-09-24 | 2005-03-24 | Novartis Ag | Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US7393529B2 (en) * | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
JP4764334B2 (ja) * | 2003-02-01 | 2011-08-31 | タノックス インコーポレーテッド | 高親和性抗ヒトIgE抗体 |
-
2004
- 2004-07-29 CA CA002552999A patent/CA2552999A1/en not_active Abandoned
- 2004-07-29 SG SG2012057212A patent/SG183683A1/en unknown
- 2004-07-29 WO PCT/US2004/024360 patent/WO2005075504A1/en active Application Filing
- 2004-07-29 KR KR1020137018993A patent/KR101562114B1/ko active IP Right Grant
- 2004-07-29 JP JP2006551035A patent/JP2008507474A/ja active Pending
- 2004-07-29 SG SG200900706-3A patent/SG149892A1/en unknown
- 2004-07-29 CN CN2011103434066A patent/CN102702359A/zh active Pending
- 2004-07-29 KR KR1020127009917A patent/KR101365375B1/ko active IP Right Grant
- 2004-07-29 KR KR1020067017609A patent/KR20070008578A/ko not_active IP Right Cessation
- 2004-07-29 AU AU2004315197A patent/AU2004315197B2/en active Active
- 2004-07-29 EP EP04779424A patent/EP1718669A4/en not_active Withdrawn
- 2004-07-29 KR KR1020147000238A patent/KR101581659B1/ko active IP Right Grant
-
2009
- 2009-06-16 AU AU2009202408A patent/AU2009202408A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0263655A2 (en) * | 1986-10-03 | 1988-04-13 | Dainippon Pharmaceutical Co., Ltd. | Novel peptides having antiallergic activity |
EP0957111A2 (en) * | 1998-04-09 | 1999-11-17 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
WO2000023477A2 (en) * | 1998-10-20 | 2000-04-27 | University Of Sheffield | Immunoglobulin variants |
WO2000050461A1 (en) * | 1999-02-25 | 2000-08-31 | Smithkline Beecham Biologicals S.A. | Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses |
WO2000074716A2 (en) * | 1999-06-08 | 2000-12-14 | Smithkline Beecham Biologicals S.A. | Ige peptides for allergy immunotherapy |
WO2002016409A2 (en) * | 2000-08-22 | 2002-02-28 | Glaxosmithkline Biologicals S.A. | Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
EP1195161A2 (en) * | 2000-08-30 | 2002-04-10 | Pfizer Products Inc. | Anti-IgE vaccines |
WO2002034288A2 (en) * | 2000-10-27 | 2002-05-02 | Smithkline Beecham Biologicals S.A. | Vaccine for treating allergy |
EP1262491A2 (en) * | 2001-05-22 | 2002-12-04 | Pfizer Products Inc. | Non-anaphylactogenic IgE vaccines |
WO2003092714A2 (en) * | 2002-04-30 | 2003-11-13 | Glaxosmithkline Biologicals S.A. | Peptide variants of ige constrained by beta-lactam bond |
Also Published As
Publication number | Publication date |
---|---|
KR101562114B1 (ko) | 2015-11-20 |
KR101365375B1 (ko) | 2014-02-19 |
KR20140021058A (ko) | 2014-02-19 |
EP1718669A1 (en) | 2006-11-08 |
AU2004315197A1 (en) | 2005-08-18 |
KR101581659B1 (ko) | 2015-12-31 |
SG183683A1 (en) | 2012-09-27 |
EP1718669A4 (en) | 2007-10-10 |
SG149892A1 (en) | 2009-02-27 |
KR20070008578A (ko) | 2007-01-17 |
CN102702359A (zh) | 2012-10-03 |
KR20130088198A (ko) | 2013-08-07 |
AU2009202408A1 (en) | 2009-07-09 |
KR20120056297A (ko) | 2012-06-01 |
WO2005075504A1 (en) | 2005-08-18 |
JP2008507474A (ja) | 2008-03-13 |
CA2552999A1 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004209638B2 (en) | High affinity anti-human IgE antibodies | |
AU2009202408A1 (en) | Identification of novel IgE epitopes | |
US20110200604A1 (en) | IDENTIFICATION OF NOVEL IgE EPITOPES | |
AU2012261739A1 (en) | Identification of novel IgE epitopes | |
AU2013263817A1 (en) | High affinity anti-human IgE antibodies | |
MXPA06008690A (es) | Identificacion de epitopos ige novedosos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |